Anixa Biosciences, Inc. (FRA:CY71)
Germany · Delayed Price · Currency is EUR 2.540
+0.040 (1.60%)
At close: Jan 30, 2026
Anixa Biosciences Revenue
Revenue
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
4
Market Cap
85.40M EUR
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Oct 31, 2025 | - | - | - |
| Oct 31, 2024 | - | - | - |
| Oct 31, 2023 | 210.00K | - | - |
| Oct 31, 2022 | - | - | - |
| Oct 31, 2021 | 512.00K | - | - |
| Oct 31, 2020 | - | - | - |
| Oct 31, 2019 | 250.00K | -862.50K | -77.53% |
| Oct 31, 2018 | 1.11M | 750.00K | 206.90% |
| Oct 31, 2017 | 362.50K | 62.50K | 20.83% |
| Oct 31, 2016 | 300.00K | -8.96M | -96.76% |
| Oct 31, 2015 | 9.26M | 5.59M | 152.36% |
| Oct 31, 2014 | 3.67M | 3.28M | 843.12% |
| Oct 31, 2013 | 388.85K | -551.16K | -58.63% |
| Oct 31, 2012 | 940.01K | -63.18K | -6.30% |
| Oct 31, 2011 | 1.00M | 272.52K | 37.30% |
| Oct 31, 2010 | 730.68K | -325.12K | -30.79% |
| Oct 31, 2009 | 1.06M | -1.01M | -48.83% |
| Oct 31, 2008 | 2.06M | 1.58M | 323.77% |
| Oct 31, 2007 | 486.85K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Netfonds AG | 239.33M |
| Meta Wolf AG | 122.26M |
| InnoTec TSS AG | 117.90M |
| audius SE | 90.95M |
| CeoTronics AG | 68.83M |
| ParTec AG | 48.67M |
| Samara Asset Group | 3.40M |
| CGRE AG | 1.12M |
Anixa Biosciences News
- 3 days ago - Insider Buying: Arnold Baskies Acquires Additional Shares of Anixa Biosciences Inc (ANIX) - GuruFocus
- 5 days ago - Anixa Biosciences (ANIX) Secures Mexican Patent for Breast Cancer Vaccine - GuruFocus
- 5 days ago - Anixa Biosciences Receives Notice of Allowance from Mexican Institute of Industrial Property (IMPI) for Patent Covering Breast Cancer Vaccine Technology - PRNewsWire
- 10 days ago - Water Tower Research Publishes Initiation of Coverage Report on Anixa Biosciences, Inc., “Anixa's T-Cell Innovations Show Breakthrough Potential in Solid Tumors” - TheNewswire
- 6 weeks ago - Anixa Biosciences (ANIX) Advances Breast Cancer Vaccine Development - GuruFocus
- 6 weeks ago - Anixa Biosciences Announces Transfer of IND for Breast Cancer Vaccine from Cleveland Clinic - PRNewsWire
- 7 weeks ago - Anixa Biosciences (ANIX) Shares Drop 21% After Phase 1 Vaccine Data - GuruFocus
- 7 weeks ago - Anixa Biosciences falls on phase 1 data for breast cancer vaccine - Seeking Alpha